Oric Pharmaceuticals (ORIC) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.38

Estimate

-$0.36

Surprise

-4.6%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Oric Pharmaceuticals (ORIC) reported a wider loss than forecast — diluted EPS of -$0.38 against the -$0.36 estimate (a 4.6% shortfall).

TrendMatrix currently rates ORIC Sell at 5.2/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -4.6% surprise compares with a +6.2% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$12.04

Price target

$17.98

Stop

$11.64

Upside to target

+49.3%

Reward-to-risk

4.8:1

Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.25B

P/E (fwd)

-7.5

52-week range

$7.23–$14.93

Off 52-week high

19.4%

RSI (14)

21

Volume vs avg

0.99×

Score today

5.2/10